Vera Therapeutics Inc(VERA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -5.87 | Insider Own | 18.81% | Shs Outstand | 72.0M | Perf Week | 10.68% |
| Market Cap | 2.23B | Forward P/E | - | EPS next Y | 31.71% | Insider Trans | -0.88% | Shs Float | 58.5M | Perf Month | -0.03% |
| Enterprise Value | 1.81B | PEG | - | EPS next Q | -1.62 | Inst Own | 98.57% | Short Float | 23.22% | Perf Quarter | -3.88% |
| Income | -0.40B | P/S | - | EPS this Y | -34.13% | Inst Trans | 8.75% | Short Ratio | 6.36 | Perf Half Y | -11.99% |
| Sales | 0.00B | P/B | 5.47 | EPS next 5Y | 49.91% | ROA | -72.32% | Short Interest | 13.59M | Perf YTD | -38.82% |
| Book/sh | 5.67 | P/C | 4.47 | EPS past 3/5Y | -11.65% -13.19% | ROE | -91.75% | 52W High | -44.73% ($56.05) | Perf Year | 4.42% |
| Cash/sh | 6.93 | P/FCF | - | Sales past 3/5Y | - | ROIC | -83.21% | 52W Low | 34.4% ($23.05) | Perf 3Y | 186.59% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -63.94% | Gross Margin | - | Volatility(W/M) | 5.09% 5.7% | Perf 5Y | 60.1% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.72 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.65 | EPS Q/Q | -27.01% | Profit Margin | - | RSI (14) | 52.8 | Recom | 1.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.65 | Sales Q/Q | - | SMA20 | 5.96% ($29.24) | Beta | 1.05 | Target Price | $73.79 |
| Payout | - | Debt/Eq | 0.18 | Earnings | 2026/11/5 | SMA50 | -3.19% ($32) | Rel Volume | 0.51 | Prev Close | $30.53 |
| Employees | 249 | LT Debt/Eq | 0.18 | EPS/Sales Surpr. | 3.54% - | SMA200 | -16.17% ($36.96) | Avg Volume(3M) | 2.14M | Price | $30.98 |
| IPO | 2021/5/14 | Option/Short | Yes/Yes | Trades | 9994 | Volume | 1,083,624 | Change | 1.47% |
A US-based clinical-stage biotech company developing therapeutics for immune-mediated kidney diseases. The company is developing treatments that target immune-related kidney disorders involving immunoglobulins, with a focus on a late-stage clinical lead candidate, advancing differentiated therapies in the kidney and immunology disease space where there is significant unmet medical need.
Over the past 1 year, on the lower side
45% below its 1-year high.
Traded less than usual. That is 51% of its average volume.
Next earnings report: November 5
5 days to go.
VERA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -34.1% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +60.1%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
23.2% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
SBIO ALPS Medical Breakthroughs ETF 0.02% 
XBI State Street SPDR S&P Biotech ETF 0.01% 
BBC Virtus Biotech Clinical Trials ETF <0.01% 
LABU Direxion Daily S&P Biotech Bull 3X ETF <0.01% 
DWAS Invesco Dorsey Wright SmallCap Momentum ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
TQQQ ProShares UltraPro QQQ 3x Shares 35.8B 
SOXL Direxion Daily Semiconductor Bull 3X ETF 24.4B 
QLD ProShares Ultra QQQ 2x Shares 14.2B 
SSO ProShares Ultra S&P500 2x Shares 8.8B 
SPXL Direxion Daily S&P 500 Bull 3X ETF 7.1B It ranks #89 of 597 in the industry
Based on market cap of $2B.
RCUS#87 Arcus Biosciences Inc $2B PER - 
HRMY#88 Harmony Biosciences Holdings Inc $2B PER 12.6 VERA#89 Vera Therapeutics Inc $2B PER - 
XNCR#90 Xencor Inc $2B PER - 
AUPH#91 Aurinia Pharmaceuticals Inc $2B PER 7.3 
FAQ
What kind of company is VERA?
VERA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VERA?
The market cap of VERA is approximately $2.2B, ranking 1,961 within its sector.
What is the 52-week high and low for VERA?
VERA has recorded a 52-week high of $56.05 and a low of $23.05.
